INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced , high-risk , HPV16/18 - positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. ((Coherus, NASDAQ: CHRS ) to evaluate the combination of INO-3112 and LOQTORZI™ (toripalimab-tpzi) as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer commonly known as throat cancer. Under the terms of the supply agreement, Coherus will provide LOQTORZI™ (toripalimab-tpzi), for a Phase 3 clinical trial to be conducted by INOVIO, pending alignment with the U.S.
https://www.benzinga.com/pressreleases/24/01/n36488058/inovio-and-coherus-announce-clinical-collaboration-to-advance-development-of-ino-3112-in-combinati